Bloom Science is a platform biotechnology company discovering and developing revolutionary new drugs targeting the gut-brain axis for the treatment and modification of diseases with high unmet need in neurology, immunology and oncology.
You’re more microbe than human – if you count all the cells in your body, only 43% are human.
Our proprietary platform developed by Bloom’s scientific co-founder Elaine Hsiao, PhD (UCLA) leverages genomic, gut microbiome, metabolomic and data analytics knowledge bases in combination with phenotypic screening to discover novel targets focused on the gut-brain axis and deliver the next generation of targeted therapeutics in areas with a clear path to deliver clinical innovation.
Our approach is to leverage naturally-occurring microbes that modulate neuroactive molecules in our brain to discover new therapeutic opportunities.
We seek to empower patients and families by bringing hope for conditions where there are few treatment options.
It is our responsibility to seek innovation, to understand the challenges faced by patients and their families, to communicate with them clearly and to openly develop medicines that transform their lives.
Our Scientific Advisory Board
NYU Professor, Department of Neurology
CSO Epilepsy Foundation
UCSF Executive Vice Chancellor and Provost,
Director of UCSF Epilepsy Center
UCLA Professor, Physiology and Psychiatry
Director of Oppenheimer Center for Neurobiology,
Author of “The Mind-Gut Connection”
Johns Hopkins University Professor, Neurology and Pediatrics
Medical Director of Pediatric Ketogenic Diet Center,
Co-author of “The
Ketogenic and Modified Atkins Diets: Treatments for Epilepsy and Other Disorders”
CEO Kindex Pharmaceutics
Member, Board of Directors, Board for Certification of Nutrition Specialists
Sign up to join us on our mission, learn more and for the latest Bloom Science news
We’re on a mission to provide a new solution to the 70 million people that are living with epilepsy.